文献速递肿瘤 PET/CT骨显像与常规 SPECT

肺淋巴管癌病:高分辨率CT与18F-FDG PET/CT诊断性能及临床病理对照

Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and 18F-FDG PET/CT in Correlation with Clinical Pathologic Outcome.
PubMed 文献 · J Nucl Med · 2019-06-21

该回顾性研究纳入94例初诊肺癌疑似肺淋巴管癌病(PLC)患者,以手术病理为金标准,比较HRCT与18F-FDG PET/CT的诊断性能。结果显示73%(69/94)病理确诊PLC,PET/CT定量参数(瘤周SUVmax、SUVmean)诊断效能显著优于定性评估和HRCT征象。

要点

  • 瘤周SUVmax诊断PLC的灵敏度97%、特异度92%、AUC 0.98。
  • HRCT支气管血管束增厚与PET/CT瘤周摄取增高定性诊断效能相似。
  • PET/CT定量参数诊断PLC优于HRCT和定性评估。

核心结论

  • 18F-FDG PET/CT定性评估与HRCT诊断PLC性能相似,但PET/CT定量参数诊断效能更优。

研究设计与样本

  • 回顾性机构批准研究,纳入94例初诊肺癌疑似PLC患者,采用双盲分析评估HRCT征象和PET/CT定性及定量参数,以手术病理为金标准。

主要发现

  • 94例中73%(69/94)病理确诊PLC。
  • PLC组支气管血管束增厚、淋巴结受累和瘤周摄取增高更常见(P < 0.009)。
  • PLC组肿瘤SUVmax、SUVmean、代谢肿瘤体积、总病灶糖酵解及瘤周SUVmax、SUVmean及其与背景比值均显著高于非PLC组(P ≤ 0.0039)。
  • 支气管血管束增厚诊断PLC的灵敏度69%、特异度83%、AUC 0.76(95%CI 0.67-0.85)。
  • 瘤周摄取增高诊断PLC的灵敏度94%、特异度84%、AUC 0.89(95%CI 0.81-0.97),与支气管血管束增厚效能相似(P = 0.054)。

关键数值与推荐

  • 瘤周SUVmax诊断PLC的灵敏度97%、特异度92%、AUC 0.98(95%CI 0.96-1.00),显著高于定性指标(P ≤ 0.025)。
  • 瘤周SUVmean诊断PLC的灵敏度94%、特异度88%、AUC 0.96(95%CI 0.92-1.00),显著高于定性指标(P ≤ 0.025)。

临床怎么用

  • 对肺癌初诊疑似PLC患者,可优先采用18F-FDG PET/CT定量参数(瘤周SUVmax、SUVmean)辅助诊断。
  • HRCT和PET/CT定性评估仍可作为补充手段,但诊断效能低于定量参数。

局限性

  • 回顾性单中心设计可能引入选择偏倚。
  • 样本量有限(94例),需外部验证。
  • 仅纳入肺癌患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rationale of this study was to investigate the performance of high-resolution CT (HRCT) versus 18F-FDG PET/CT for the diagnosis of pulmonary lymphangitic carcinomatosis (PLC). Methods: In this retrospective institution-approved study, 94 patients addressed for initial staging of lung cancer with suspicion of PLC were included. Using double-blind analysis, we assessed the presence of signs favoring PLC on HRCT (smooth or nodular septal lines, subpleural nodularity, peribronchovascular thickening, satellite nodules, lymph node enlargement, and pleural effusion). 18F-FDG PET/CT images were reviewed to qualitatively evaluate peritumoral uptake and to quantify tracer uptake in the tumoral and peritumoral areas. Histology performed on surgical specimens served as the gold standard for all patients. Results: Among 94 included patients, 73% (69/94) had histologically confirmed PLC. Peribronchovascular thickening, lymph node involvement, and increased peritumoral uptake were more often present in patients with PLC (P < 0.009). Metabolic variables, including tumor SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis, as well as peritumoral SUVmax, SUVmean, and their respective ratios to background, were significantly higher in the PLC group than in the non-PLC group (P ≤ 0.0039). Sensitivity, specificity, and area under the receiver-operating-characteristic curve for peribronchovascular thickening (69%, 83%, and 0.76, respectively; 95% confidence interval [95%CI], 0.67-0.85) and increased peritumoral uptake (94%, 84%, and 0.89, respectively; 95%CI, 0.81-0.97) were similar (P = 0.054). For detecting PLC, sensitivity, specificity, and area under the receiver-operating-characteristic curve were significantly higher, at 97%, 92%, and 0.98, respectively (95%CI, 0.96-1.00), for peritumoral SUVmax and 94%, 88%, and 0.96, respectively (95%CI, 0.92-1.00), for peritumoral SUVmean (all P ≤ 0.025). Conclusion: Qualitative evaluation of 18F-FDG PET/CT and HRCT perform similarly for the diagnosis of PLC, with both being outperformed by 18F-FDG PET/CT quantitative parameters.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jreige M, Dunet V, Letovanec I, et al. Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and 18F-FDG PET/CT in Correlation with Clinical Pathologic Outcome. J Nucl Med. 2019. PMID: 31227574. doi:10.2967/jnumed.119.229575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。